The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.
about
Vitamin K for improved anticoagulation control in patients receiving warfarinVitamin K for improved anticoagulation control in patients receiving warfarinNew oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic eventsOral anticoagulants: pharmacodynamics, clinical indications and adverse effectsCharacterization and purification of the vitamin K1 2,3 epoxide reductases system from rat liverHypertensive patients show delayed wound healing following total hip arthroplasty.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy.Review on natural coumarin lead compounds for their pharmacological activityA comparison of the effect of salmeterol and salbutamol in normal subjects.A comprehensive model for the humoral coagulation network in humans.Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen.Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study.Four factor prothrombin complex concentrate (human): review of the pharmacology and clinical application for vitamin K antagonist reversal.A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins.GGCX-Associated Phenotypes: An Overview in Search of Genotype-Phenotype Correlations.The long-term effects of the rodenticide, brodifacoum, on blood coagulation and vitamin K metabolism in ratsAnticoagulation after intracoronary stent insertion.Factors affecting warfarin therapy following cardiac valve surgery.Novel splice site mutations in the gamma glutamyl carboxylase gene in a child with congenital combined deficiency of the vitamin K-dependent coagulation factors (VKCFD).Effects of warfarin and L-carnitine on hemostatic function and oxidative stress in streptozotocin-induced diabetic rats.Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety.Vitamin K epoxide reductase complex subunit 1 (VKORC1 ) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study.Phenotyping of CYP 4501A2 Activity by Total Overnight Salivary Caffeine Assessment (TOSCA) in Patients on Warfarin Treatment: A Cross-Sectional Study.
P2860
Q24194649-7E1A2A3C-FBD3-48F5-8081-5628D3452B32Q24202915-043AA77A-D3F5-4A2E-88C3-BA1C1441E881Q28080616-1F7F46BA-A306-46BE-8189-3753FE527A80Q28319507-70B4AA84-3F5C-4BB1-AC59-621FAD6E3D30Q28568888-1D7F84D0-477E-4ECA-8931-650FD48A4F5DQ33996978-5D687C70-C974-4095-97FA-EE471CC8FF71Q34252907-6D96EF11-F4BC-49FA-9432-D3AE0332067BQ34273608-16EE2914-ABA3-4438-8071-4576EE499E56Q34339290-F3FA4D95-9905-4776-9D6A-543314A482C6Q34402874-4BC1B388-98D7-4F2A-B755-655CA9DC6ED8Q34986144-A25F7873-3378-42CD-8002-C9BAA0AF460DQ36624112-BB677AF5-0084-47A4-9281-878029378B77Q37378994-B9C76800-73F4-4709-A2DA-9CC2B7FE9602Q37473370-530D0B33-E4FA-4A2A-A247-03CAFDAF75E2Q38197728-A9F3CFA5-7E4A-4A7A-BE05-41214220C986Q38730441-DEF4715E-C2BE-43D2-8556-0150E0C8D1A9Q39104527-72F949A5-8F65-407A-8A3A-E350BF88D1B7Q42125855-BE19D403-A8B8-4D21-91E3-4C92922CC9FFQ42578643-123D274D-F526-4FDE-A690-4E8A5A2E6B84Q44229917-4687AA62-F26D-488E-AB50-857718A29DE2Q46064294-50B0EF7C-AF05-4A70-B5AC-D5CFC75A18B9Q46251562-9FEEA766-0967-4C42-8979-8FF9B0EC5BB0Q46419430-60EB46F9-6A47-4D1F-B992-DB4C2B42C518Q46605168-36FFC547-42FA-48F1-B445-3EE9DAADB401Q48577324-710AEFDF-39A8-477A-BB48-14EDE47F26C8
P2860
The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh-hant
name
The relationship between inhib ...... factor activity with warfarin.
@en
The relationship between inhib ...... factor activity with warfarin.
@nl
type
label
The relationship between inhib ...... factor activity with warfarin.
@en
The relationship between inhib ...... factor activity with warfarin.
@nl
prefLabel
The relationship between inhib ...... factor activity with warfarin.
@en
The relationship between inhib ...... factor activity with warfarin.
@nl
P2093
P2860
P1476
The relationship between inhib ...... factor activity with warfarin.
@en
P2093
A M Breckenridge
B P Haynes
F E Preston
I A Choonara
S Cholerton
P2860
P356
10.1111/J.1365-2125.1988.TB03274.X
P407
P577
1988-01-01T00:00:00Z